ORR and MRD based on prior treatment history
Subgroup . | ORR* . | MRD-negative rate (10−5)† . | ||
---|---|---|---|---|
Patients in group, n % Patients in group, n % | ||||
All response evaluable | 82 | 84 | 11 | 36 |
Refractory to lenalidomide | 48 | 79 | 5 | 20 |
Lenalidomide exposed but not refractory | 30 | 90 | 4 | 50 |
Refractory to bortezomib | 25 | 84 | 26 | 8 |
Refractory to IMiD | 53 | 77 | 5 | 20 |
IMiD exposed but not refractory | 29 | 97 | 6 | 50 |
Refractory to PI and IMiD | 24 | 83 | 2 | 0 |
Cytogenetic risk‡ | ||||
High§ | 13 | 69 | 3 | 67 |
Standard | 52 | 90 | 6 | 33 |
Subgroup . | ORR* . | MRD-negative rate (10−5)† . | ||
---|---|---|---|---|
Patients in group, n % Patients in group, n % | ||||
All response evaluable | 82 | 84 | 11 | 36 |
Refractory to lenalidomide | 48 | 79 | 5 | 20 |
Lenalidomide exposed but not refractory | 30 | 90 | 4 | 50 |
Refractory to bortezomib | 25 | 84 | 26 | 8 |
Refractory to IMiD | 53 | 77 | 5 | 20 |
IMiD exposed but not refractory | 29 | 97 | 6 | 50 |
Refractory to PI and IMiD | 24 | 83 | 2 | 0 |
Cytogenetic risk‡ | ||||
High§ | 13 | 69 | 3 | 67 |
Standard | 52 | 90 | 6 | 33 |